Pharmaceutical

Five things for pharma marketers to know: Friday, October 31

Five things for pharma marketers to know: Friday, October 31

Bristol-Myers Squibb's Opdivo improves survival rate in lung cancer patients; Businessweek says new Viagra spot targets a younger audience; NIH launches database to keep track of different countries' clinical trial regulations

Five things for pharma marketers to know: Thursday, October 30

Five things for pharma marketers to know: Thursday, October 30

Sanofi courts AstraZeneca CEO Soriot; Teva CEO optimistic on Copaxone patent ruling; AstraZeneca scores approval of diabetes combo drug.

Forbes's Matthew Herper sounds off on Viehbacher firing

Herper writes that Sanofi—without Viehbacher—is at risk of moving too slowly in an increasingly competitive industry.

Five things for pharma marketers to know: Wednesday, October 29

Five things for pharma marketers to know: Wednesday, October 29

Sanofi CEO fired; Sovaldi sales slow; Ranbaxy CEO affirms generic Nexium rights.

Pfizer undeterred from tax inversion deals

Despite the Treasury's crackdown on inversions, CEO Ian Read says they would still invert for the right deal.

Amgen has no plans to split up, layoffs continue

The drugmaker plans to cut 600-1,100 jobs next year.

Diabetes competition muddles Sanofi's future, despite strong sales

Diabetes competition muddles Sanofi's future, despite strong sales

Sanofi is expected to slash prices of its diabetes products to retain US market access.

A generic Nexium, at long last?

A generic Nexium, at long last?

With Ranbaxy's failure to launch a low-cost version of the acid reflux drug, pressure is mounting on FDA to speed a generic to market.

Five things for pharma marketers to know: Tuesday, October 28

Five things for pharma marketers to know: Tuesday, October 28

Sanofi CEO says diabetes sales will slow in 2015; Takeda/Lilly Actos settlement slashed by 99%; study says Sovaldi is cost-effective for prisoners.

FDA request delays Sarepta's Duchenne drug

The drug is now expected to be filed by mid-2015, rather than by year's end.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.